The resurgence of mycobacterial tuberculosis (TB) is attributed to the appearance of strains of the pathogen resistant to current anti-TB drugs.  This has spurred interest in the development of new chemotherapeutic agents against TB as well as new vaccines for the prevention of the disease.  The nonreducing ends of the mycobacterial cell wall polysaccharide lipoarabinomannan is terminated with a hexasaccharide motif (1) thought to be involved in immunological events associated with mycobacterial infection and is also shown to be recognized by an antibody generated against Mycobacterium leprae LAM [1].  In an effort to provide large amounts of this hexasaccharide for the development of a viable hapten for vaccine generation, we have investigated a new route to this motif [2,3].  In the route reported here, the key step is a stereoselective glycosylation between disaccharide 2 and acceptor 3, which provides a pentasaccharide that can be further elaborated to 1.